Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers

Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030”.”

The report features an extensive study of the current market landscape and future opportunities…

The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity

Roots Analysis has announced the addition of “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030” report to its list of offerings.

Owing to various reasons, the demand for cell therapies is anticipated to increase over the…

Roots Analysis has done a detailed study on Patient Recruitment and Retention Services Marker, 2019-2030.”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 300+ page report, which features 90+ figures and 140+ tables, please visit this -…

A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies, prompting them to enlist the services of specialty service providers. Presently, close to 140 companies are actively offering patient recruitment and retention services. Majority of these players possess vast service portfolios and utilize diverse patient outreach methods to recruit study participants across different…